Hexarelin-induced growth hormone response in short stature. Comparison with growth hormone-releasing hormone plus pyridostigmine and arginine plus estrogen.

J Endocrinol Invest

Divisione di Auxologia, Ospedale San Giuseppe IRCCS, Istituto Auxologico Italiano, Verbania Intra, Italy.

Published: May 1999

AI Article Synopsis

Article Abstract

Unlabelled: Hexarelin (HEX) is a synthetic hexapeptide with strong GH-stimulating activity. We evaluated GH response (expressed as maximum value after stimulus [Cmax] and as area under the curve [AUC]) to HEX at the doses of 1 microg/kg i.v. (HEX 1) and 2 microg/kg i.v. (HEX 2), in comparison with the responses to GHRH (1 microg/kg i.v.) + pyridostigmine (PD, 60 mg po) and to arginine (ARG, 0.5 mg/kg i.v.) + ethinylestradiol (EE, 1 mg/day po for 3 days before the stimulation), in 5 subjects with familial short stature (FSS), 11 with constitutional growth delay (CGD), 6 with GH neurosecretory dysfunction (NSD), and 5 with isolated growth hormone deficiency (GHD). Cmax and AUC after HEX 1 were 26.8+/-10.5 ng/ml and 1448+/-514 ng/min x ml in FSS, 23.6+/-14.4 ng/ml and 1146+/-750 ng/min x ml in CGD, 36.9+/-21.5 ng/ml and 2048+/-1288 ng/min x ml in NSD, 9.4+/-5.8 ng/ml and 498+/-200 ng/min x ml in GHD (Cmax and AUC in FSS and CGD, p<0.05 vs GHD). Cmax and AUC after HEX 2 were 37.7+/-16 ng/ml and 1979+/-888 ng/min x ml in FSS, 32.5+/-16.2 ng/ml and 1613+/-237 ng/min x ml in CGD, 39.7+/-20.7 ng/ml and 2366+/-1569 ng/min xml in NSD, 13.4+/-4.2 ng/ml and 645+/-293 ng/min x ml in GHD (Cmax in FSS, CGD and NSD p<0.01 vs GHD; AUC in NSD, p<05 vs GHD). Cmax and AUC after GHRH+/-PD were 46.6+/-8.8 ng/ml and 3294+/-1031 ng/min x ml in FSS, 25.9+/-11.2 ng/ml and 1464+/-735 ng/min x ml in CGD, 38.8+/-21.7 ng/ml and 2428+/-1399 ng/min x ml in NSD, 8.4+/-6.2 ng/ml and 685+/-572 ng/min x ml in GHD (Cmax and AUC in FSS, p<0.001 vs CGD and GHD; Cmax in CGD and NSD, p<0.001 vs GHD). Cmax and AUC after ARG+EE were 21.3+/-4.2 ng/ml and 1432+/-514 ng/min x ml in FSS, 14.8+/-10 ng/ml and 805+/-489 ng/min x ml in CGD, 22.2+/-12.8 ng/ml and 1199+/-309 ng/min x ml in NSD, 4.6+/-2.5 ng/ml and 247+/-191 ng/min x ml in GHD (Cmax and AUC in FSS, CGD and NSD, p<0.01 vs GHD). Specificity was 62% for HEX 1 and 75% for HEX 2, GHRH+PD and ARG+EE. From a diagnostic point of view, HEX 1 + HEX 2 was the association with the largest percentage of false positives (20% in FSS, 27% in CGD and 33% in NSD), HEX 1 +GHRH+PD resulted in 9% in CGD, while the combined use of HEX 1 or HEX 2 with GHRH+PD or ARG+EE and of GHRH+PD with ARG+EE did not show false positive responses.

In Conclusion: I) the most effective dose of HEX was 2 microg/kg i.v.; 2) HEX did not show more specificity than GHRH+PD and ARG+EE; 3) the association of GHRH+PD with ARG+EE could yield the best results at lower costs, confirming these tests as first-line tools in evaluating GH secretion.

Download full-text PDF

Source
http://dx.doi.org/10.1007/BF03343574DOI Listing

Publication Analysis

Top Keywords

growth hormone
8
short stature
8
pyridostigmine arginine
8
microg/kg hex
8
ghd cmax
8
cmax auc
8
hex
5
hexarelin-induced growth
4
hormone response
4
response short
4

Similar Publications

Critical Insights into LEAP2 Biology and Physiological Functions: Potential Roles Beyond Ghrelin Antagonism.

Endocrinology

January 2025

Grupo de Neurofisiología- Instituto Multidisciplinario de Biología Celular (IMBICE) (Consejo Nacional de Investigaciones Científicas y Técnicas, Universidad de La Plata, Comisión de Investigaciones Científicas de la Provincia de Buenos Aires), La Plata, Argentina.

Liver-expressed antimicrobial peptide 2 (LEAP2) has recently emerged as a novel hormone that reduces food intake and glycemia by acting through the growth hormone secretagogue receptor (GHSR), also known as the ghrelin receptor. This discovery has led to a fundamental reconceptualization of GHSR's functional dynamics, now understood to be under a dual and opposing regulation. LEAP2 exhibits several distinctive features.

View Article and Find Full Text PDF

ERF114/115/109 are essential for jasmonate-repressed non-canonical JAZ8 activity in JA signaling.

Cell Rep

January 2025

The Key Laboratory of Plant Development and Environmental Adaptation Biology, Ministry of Education, Shandong Key Laboratory of Precision Molecular Crop Design and Breeding, School of Life Science, Shandong University, Qingdao, Shandong 266237, China. Electronic address:

Jasmonate (JA), a key plant hormone, regulates various aspects of plant development and stress responses, primarily through the degradation of canonical jasmonate-ZIM domain (JAZ) proteins by the SCF complex. While JAZ8, a non-canonical JAZ protein lacking the degron signal, has been shown to repress JA responses, the mechanism by which JA inhibits JAZ8 activity remains unclear. Here, we demonstrate that Arabidopsis ethylene response factor 114 (ERF114), ERF115, and ERF109 regulate JA signaling through interacting with JAZ8.

View Article and Find Full Text PDF

Background: Early menarche is associated with both physical and psychosocial problems. Based on psychological and physical health considerations, for girls with early menarche, some parents and physicians may elect to use gonadotropin-releasing hormone agonists (GnRHa) to delay menstruation. This study aimed to explore the effects of GnRHa treatment on the final height of girls with early menarche and build the models to predict the final adult height (FAH).

View Article and Find Full Text PDF

Introduction: Exercise is vital in preventing and treating obesity. Despite its importance, the understanding of how exercise influences childhood obesity at the biochemical level is limited. In this study, we explore the effects of a 16-week exercise program (EP) on body composition, physical fitness, and the blood levels of hormones related to obesity.

View Article and Find Full Text PDF

Objective: To investigate the effects of allylestrenol on sex hormone levels and delivery outcomes in women with threatened abortion.

Methods: This retrospective analysis examined clinical data of patients with threatened abortion treated at Huzhou Maternity & Child Health Care Hospital from January 1, 2021, to December 31, 2022. A total of 149 eligible patients were screened and divided into two groups: a control group (n=75) treated with progesterone capsules from January to December 2021, and an observation group (n=74) treated with allylestrenol from January to December 2022.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!